Your browser doesn't support javascript.
loading
Prognostic value of baseline and early response FDG-PET/CT in patients with refractory and relapsed aggressive B-cell lymphoma undergoing CAR-T cell therapy.
Georgi, Thomas Walter; Kurch, Lars; Franke, Georg-Nikolaus; Jentzsch, Madlen; Schwind, Sebastian; Perez-Fernandez, Carmen; Petermann, Naima; Merz, Maximilian; Metzeler, Klaus; Borte, Gudrun; Hoffmann, Sandra; Herling, Marco; Denecke, Timm; Kluge, Regine; Sabri, Osama; Platzbecker, Uwe; Vucinic, Vladan.
Afiliación
  • Georgi TW; Department of Nuclear Medicine, University of Leipzig, Leipzig, Germany.
  • Kurch L; Department of Nuclear Medicine, University of Leipzig, Leipzig, Germany.
  • Franke GN; Medical Clinic I, Department of Hematology, Cellular Therapy and Hemostaseology, University of Leipzig, Liebigstr. 22, 04103, Leipzig, Germany.
  • Jentzsch M; Medical Clinic I, Department of Hematology, Cellular Therapy and Hemostaseology, University of Leipzig, Liebigstr. 22, 04103, Leipzig, Germany.
  • Schwind S; Medical Clinic I, Department of Hematology, Cellular Therapy and Hemostaseology, University of Leipzig, Liebigstr. 22, 04103, Leipzig, Germany.
  • Perez-Fernandez C; Department of Radiology, University of Leipzig, Leipzig, Germany.
  • Petermann N; Department of Radiology, University of Leipzig, Leipzig, Germany.
  • Merz M; Medical Clinic I, Department of Hematology, Cellular Therapy and Hemostaseology, University of Leipzig, Liebigstr. 22, 04103, Leipzig, Germany.
  • Metzeler K; Medical Clinic I, Department of Hematology, Cellular Therapy and Hemostaseology, University of Leipzig, Liebigstr. 22, 04103, Leipzig, Germany.
  • Borte G; Department of Radiology, University of Leipzig, Leipzig, Germany.
  • Hoffmann S; Medical Clinic I, Department of Hematology, Cellular Therapy and Hemostaseology, University of Leipzig, Liebigstr. 22, 04103, Leipzig, Germany.
  • Herling M; Medical Clinic I, Department of Hematology, Cellular Therapy and Hemostaseology, University of Leipzig, Liebigstr. 22, 04103, Leipzig, Germany.
  • Denecke T; Department of Radiology, University of Leipzig, Leipzig, Germany.
  • Kluge R; Department of Nuclear Medicine, University of Leipzig, Leipzig, Germany.
  • Sabri O; Department of Nuclear Medicine, University of Leipzig, Leipzig, Germany.
  • Platzbecker U; Medical Clinic I, Department of Hematology, Cellular Therapy and Hemostaseology, University of Leipzig, Liebigstr. 22, 04103, Leipzig, Germany.
  • Vucinic V; Medical Clinic I, Department of Hematology, Cellular Therapy and Hemostaseology, University of Leipzig, Liebigstr. 22, 04103, Leipzig, Germany. vladan.vucinic@medizin.uni-leipzig.de.
J Cancer Res Clin Oncol ; 149(9): 6131-6138, 2023 Aug.
Article en En | MEDLINE | ID: mdl-36662305
PURPOSE: Chimeric antigen receptor (CAR)-T cells are a viable treatment option for patients with relapsed or refractory (r/r) aggressive B-cell lymphomas. The prognosis of patients who relapse after CAR-T cell treatment is dismal and factors predicting outcomes need to be identified. Our aim was to assess the value of FDG-PET/CT in terms of predicting patient outcomes. METHODS: Twenty-two patients with r/r B-cell lymphoma who received CAR-T cell treatment with tisagenlecleucel (n = 17) or axicabtagene ciloleucel (n = 5) underwent quantitative FDG-PET/CT before (PET-0) and 1 month after infusion of CAR-T cells (PET-1). PET-1 was classified as complete metabolic response (CMR, Deauville score 1-3) or non-CMR (Deauville score 4-5). RESULTS: At the time of PET-1, 12/22 (55%) patients showed CMR, ten (45%) patients non-CMR. 7/12 (58%) CMR patients relapsed after a median of 223 days, three of them (25%) died. 9/10 (90%) non-CMR patients developed relapse or progressive disease after a median of 91 days, eight of them (80%) died. CMR patients demonstrated a significantly lower median total metabolic tumor volume (TMTV) in PET-0 (1 ml) than non-CMR patients (225 ml). CONCLUSION: Our results confirm the prognostic value of PET-1. 42% of all CMR patients are still in remission 1 year after CAR T-cell treatment. 90% of the non-CMR patients relapsed, indicating the need for early intervention. Higher TMTV before CAR-T cell infusion was associated with lower chances of CMR.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Linfoma de Células B / Linfoma de Células B Grandes Difuso / Receptores Quiméricos de Antígenos Tipo de estudio: Etiology_studies / Prognostic_studies Límite: Humans Idioma: En Revista: J Cancer Res Clin Oncol Año: 2023 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Alemania
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Linfoma de Células B / Linfoma de Células B Grandes Difuso / Receptores Quiméricos de Antígenos Tipo de estudio: Etiology_studies / Prognostic_studies Límite: Humans Idioma: En Revista: J Cancer Res Clin Oncol Año: 2023 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Alemania